Parabilis Q2 FY26 net loss widens to $52.46 million; revenue rises to $148,000
PBLS•Q2 results and expenses
Parabilis Medicines posted a Q2 net loss of USD 52.46 million, widening from USD 34.81 million a year earlier.
- Revenue rose to USD 148,000.
- R&D costs climbed to USD 39.38 million from USD 30.13 million, driven by zolucatetide development and higher employee-related costs.
- G&A expenses rose to USD 11.66 million from USD 6.39 million on higher headcount-related costs and public-company spending.
Cash position and development timeline
Cash, cash equivalents, and marketable securities totaled USD 1.1 billion at June 30, and the company said operations are expected to be funded into 2030.
- The zolucatetide Phase 3 desmoid trial is targeted for H1 2027.
- FDA discussions are planned for Q4 2026.
- Additional data are expected in Q4.
